A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.

[1]  D. Valla,et al.  EASL Clinical Practice Guidelines: Vascular diseases of the liver. , 2016, Journal of hepatology.

[2]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[3]  P. Hu,et al.  A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study , 2015, Virology Journal.

[4]  Xiaomin Yan,et al.  Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. , 2015, World journal of gastroenterology.

[5]  Xu Li,et al.  Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. , 2015, World journal of gastroenterology.

[6]  T. Berg,et al.  P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study , 2015 .

[7]  Hong Tang,et al.  The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks , 2015, Indian journal of medical microbiology.

[8]  Q. Ning,et al.  Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues , 2015, Gut.

[9]  Hong Tang,et al.  Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon , 2015, Theranostics.

[10]  M. Yeh,et al.  Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. , 2014, Journal of hepatology.

[11]  Y. Paik,et al.  Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen‐positive chronic hepatitis B patients , 2014, Journal of gastroenterology and hepatology.

[12]  Yiyin Wang,et al.  Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  M. Akın,et al.  A Low Serum γ-Glutamyltransferase Level Predicts a Sustained Virological Response in Patients with Chronic Hepatitis C Genotype 1 , 2014, Gut and liver.

[14]  Huy A. Nguyen,et al.  Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice , 2013, Journal of gastroenterology and hepatology.

[15]  Fu-Sheng Wang,et al.  Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study. , 2012, Journal of hepatology.

[16]  Sheng-Nan Lu,et al.  A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. , 2012, The Journal of antimicrobial chemotherapy.

[17]  A. Bertoletti,et al.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection , 2011, Gut.

[18]  S. Ahn,et al.  Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B , 2011, Digestion.

[19]  Soon Sun Kim,et al.  Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B , 2011, Journal of medical virology.

[20]  Y. Liaw,et al.  Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection , 2010, Digestive Diseases and Sciences.

[21]  Y. Liaw.  HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B , 2009, Hepatology international.

[22]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[23]  J. Everhart,et al.  Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. , 2009, Gastroenterology.

[24]  Ding‐Shinn Chen,et al.  A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine‐treated chronic hepatitis B patients , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[25]  T. Piratvisuth.  Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B , 2008, Hepatology international.

[26]  P. Marcellin,et al.  HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B , 2008, Hepatology.

[27]  Y. Liaw,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2007, The New England journal of medicine.

[28]  O. Wagner,et al.  Gamma glutamyltransferase and long-term survival: is it just the liver? , 2007, Clinical chemistry.

[29]  Y. Rotman,et al.  Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection , 2006, Journal of viral hepatitis.

[30]  Z. Zou,et al.  Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B1 , 2006, The Journal of Immunology.

[31]  F. Chisari,et al.  Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins , 2005, Journal of Virology.

[32]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[33]  Y. Liaw.  Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti‐hepatitis B virus therapy 1 , 2003, Journal of gastroenterology and hepatology.

[34]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[35]  Y. Liaw,et al.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.

[36]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .